Impact of Interleukin-6 in Hematological Malignancies
- 19 July 2013
- journal article
- review article
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 40 (5), 336-343
- https://doi.org/10.1159/000354194
Abstract
Almost 3 decades have passed since the discovery and cloning of IL-6, and a tremendous amount of work has contributed to the current knowledge of the biological functions of this cytokine, its receptor, and the signaling pathways that are activated. The understanding of the role of IL-6 in human disease has led to the development of novel therapeutic strategies that block the biological functions of IL-6. In clinical studies, IL-6 and IL-6 receptor antibodies have proven efficacy in rheumatoid arthritis, systemic juvenile idiopathic arthritis, and Castleman's disease, conditions that are known to be driven by IL-6. The focus of this overview is the role of IL-6 in the pathophysiology of hematological malignancies.Keywords
This publication has 70 references indexed in Scilit:
- Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cellsBlood Cancer Journal, 2013
- HHV-8–encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in miceBlood, 2012
- Targeting the Interleukin-6/Jak/Stat Pathway in Human MalignanciesJournal of Clinical Oncology, 2012
- An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationBlood, 2012
- Viral Interleukin-6: Role in Kaposi's Sarcoma-Associated Herpesvirus–Associated MalignanciesJournal of Interferon & Cytokine Research, 2011
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signalingJCI Insight, 2011
- IL-6 and MYC collaborate in plasma cell tumor formation in miceBlood, 2010
- A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple MyelomaClinical Cancer Research, 2009
- Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cellsin vitroandin vivoMolecular Cancer Therapeutics, 2009
- Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.JCI Insight, 1990